Antidiabetic Drug

Antidiabetic Drug Market Outlook

The global antidiabetic drug market is anticipated to reach approximately $145 billion by 2035, growing at a CAGR of around 6.2% from 2025 to 2035. The increasing prevalence of diabetes, driven largely by rising obesity rates, sedentary lifestyles, and aging populations, is one of the primary catalysts for this growth. Additionally, the demand for advanced treatment options, including personalized medicine and combination therapies, is significantly pushing the market forward. Innovative drug formulations and the introduction of new classes of antidiabetic agents are also expected to contribute positively to market expansion. Moreover, ongoing research and development efforts aimed at enhancing drug efficacy and patient adherence are fostering a competitive landscape that promises substantial advancements in diabetic care.

Growth Factor of the Market

Several factors are driving the growth of the antidiabetic drug market. First and foremost, the rising incidence of diabetes worldwide is a significant contributor, with the International Diabetes Federation estimating that over 537 million adults were living with diabetes in 2021. This number is projected to rise considerably in the coming years, leading to increased demand for effective treatment options. Furthermore, advancements in drug development technologies, including bioengineering and nanotechnology, are allowing pharmaceutical companies to create more effective and safer antidiabetic medications. The growing awareness of diabetes management among healthcare professionals and patients is also driving market growth, as individuals are increasingly seeking out medications that provide optimal glycemic control. Additionally, favorable reimbursement policies and government initiatives aimed at improving diabetes management are contributing to a supportive market environment. Finally, the rising trend of preventive healthcare is encouraging more individuals to seek early interventions, which further drives the demand for antidiabetic drugs.

Key Highlights of the Market

• Continuous rise in global diabetes prevalence necessitating effective treatment options.
• Emerging drug classes and advanced therapeutics enhancing treatment regimens.
• Growing investment in research and development for innovative diabetes management therapies.
• Increased awareness and education regarding diabetes prevention and management.
• Favorable regulatory environment supporting the approval of new medications.

By Product Type

Insulin:

Insulin remains a fundamental treatment for diabetes, particularly for individuals with Type 1 diabetes, as well as for those with advanced Type 2 diabetes where oral medications fail to maintain adequate glycemic control. Insulin therapy has evolved significantly with the introduction of rapid-acting, long-acting, and ultra-long-acting insulins, which allow for more flexible dosing and improved patient adherence. Innovations in insulin delivery devices, such as pens and pumps, have also enhanced the ease of use and convenience for patients. Moreover, biosimilar insulins are emerging in the market, offering cost-effective alternatives that may improve patient access. The ongoing advancements in insulin formulations and delivery mechanisms are expected to bolster the insulin segment in the antidiabetic drug market, catering to the diverse needs of patients.

Biguanides:

Biguanides, particularly Metformin, are among the most prescribed oral antidiabetic medications globally. They are primarily used for the treatment of Type 2 diabetes and are often the first line of therapy due to their efficacy in lowering blood glucose levels and favorable safety profile. Metformin works by reducing hepatic glucose production and improving insulin sensitivity. The availability of generic formulations has made biguanides an affordable option, enhancing their accessibility for patients. Additionally, research into the cardiovascular benefits of Metformin has further solidified its position within diabetes management. The biguanides segment is expected to maintain steady growth as more healthcare providers recognize the importance of this drug class in comprehensive diabetes treatment strategies.

Sulfonylureas:

Sulfonylureas are another important class of oral antidiabetic agents that stimulate insulin secretion from pancreatic beta cells. They are often prescribed for individuals with Type 2 diabetes who are not achieving adequate glycemic control with Metformin alone. Although sulfonylureas have been effective in lowering blood glucose levels, concerns regarding their potential for hypoglycemia and weight gain have prompted healthcare providers to consider alternative therapies. Nevertheless, this drug class remains popular due to its long-standing track record and clinical efficacy, particularly for patients requiring immediate blood sugar control. The sulfonylureas market segment is anticipated to experience gradual growth, supported by ongoing research into new formulations and combination therapies that can enhance their effectiveness and minimize side effects.

DPP-4 Inhibitors:

Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a newer class of oral antidiabetic medications that work by increasing incretin levels, which in turn stimulate insulin release and decrease glucagon levels. This mechanism allows for better postprandial glucose control with a lower risk of hypoglycemia. DPP-4 inhibitors are particularly appealing to patients due to their favorable side effect profiles and ease of use, as they can be taken without regard to meals. As the demand for diabetes therapies continues to evolve, DPP-4 inhibitors have carved a niche in the treatment landscape, particularly for patients with Type 2 diabetes. The segment is expected to grow due to ongoing research into their long-term benefits and potential adjunctive roles in combination therapy regimens.

SGLT-2 Inhibitors:

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a significant advancement in the management of Type 2 diabetes. These medications work by promoting the excretion of glucose through urine, thereby lowering blood glucose levels and offering additional benefits such as weight loss and reduced blood pressure. Furthermore, SGLT-2 inhibitors have shown renal protective effects, making them an attractive option for patients with diabetic kidney disease. The growing body of evidence supporting the cardiovascular and renal benefits of SGLT-2 inhibitors has led to their increased adoption in clinical practice. This segment is expected to witness robust growth as more healthcare providers recognize the multifaceted advantages these drugs offer for comprehensive diabetes management.

By Application

Type 1 Diabetes:

Type 1 diabetes, characterized by the autoimmune destruction of insulin-producing beta cells in the pancreas, necessitates lifelong insulin therapy for blood glucose control. Patients with Type 1 diabetes are typically diagnosed at a young age and require a tailored approach to manage their condition effectively. The availability of various insulin formulations and delivery devices has enabled enhanced management of this chronic condition. Continuous glucose monitoring systems and insulin pumps have further improved glycemic control and patient satisfaction. The Type 1 diabetes application segment is expected to remain stable, with ongoing advancements in insulin technologies and patient education playing crucial roles in improving outcomes.

Type 2 Diabetes:

Type 2 diabetes, the most prevalent form of diabetes, is primarily driven by insulin resistance and is often associated with obesity and sedentary lifestyles. The management of Type 2 diabetes typically involves a combination of lifestyle modifications and pharmacotherapy. A wide range of antidiabetic medications is available, including oral agents and injectable options. As the global obesity epidemic continues to rise, the number of individuals diagnosed with Type 2 diabetes is expected to increase significantly. This growing patient population will drive demand for a diverse array of treatment options, positioning the Type 2 diabetes application segment for substantial growth in the coming years.

Gestational Diabetes:

Gestational diabetes occurs during pregnancy and can pose risks for both the mother and child if left unmanaged. The management of gestational diabetes primarily focuses on lifestyle modifications and, when necessary, pharmacological interventions to maintain blood glucose levels within target ranges. Insulin remains the preferred treatment for women with gestational diabetes, although some oral agents may also be employed. The increasing awareness of the potential complications associated with gestational diabetes is leading to enhanced screening and management strategies. As maternal health becomes a greater focus in prenatal care, the gestational diabetes application segment is likely to witness steady growth in the antidiabetic drug market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of antidiabetic drugs, particularly for patients requiring inpatient care and those managing complex diabetes-related complications. These pharmacies often provide a comprehensive range of medications, including insulin and oral antidiabetic agents, tailored to the specific needs of patients during their hospital stay. Additionally, hospital pharmacists are integral to medication management and patient education, ensuring that discharged patients understand their treatment regimens. The hospital pharmacy distribution channel is expected to remain a vital segment as healthcare systems prioritize effective diabetes management and patient education within hospital settings.

Retail Pharmacies:

Retail pharmacies serve as the most accessible point for patients to obtain antidiabetic medications. They offer a wide variety of oral and injectable antidiabetic drugs, making it convenient for patients to fill prescriptions and receive counseling on medication adherence. The growth of retail pharmacy chains and the increasing focus on patient-centered care have further enhanced the role of retail pharmacies in diabetes management. Programs that promote medication synchronization and adherence are being implemented to improve patient outcomes. The retail pharmacy distribution channel is expected to witness continuous growth as more individuals seek convenient access to diabetes medications.

Online Pharmacies:

The emergence of online pharmacies has transformed the way patients access antidiabetic medications, providing the convenience of home delivery and often lower prices compared to traditional pharmacies. With the increasing prevalence of e-commerce and the growing trend of telehealth, online pharmacies are becoming an attractive option for patients managing chronic conditions such as diabetes. The accessibility of online pharmacies is especially beneficial for individuals in remote areas or those with mobility challenges. As digital solutions continue to advance, the online pharmacy distribution channel is expected to experience significant growth, catering to the evolving needs of diabetes patients.

By Ingredient Type

Metformin:

As one of the most widely used antidiabetic medications, Metformin is the cornerstone of Type 2 diabetes treatment. It works by decreasing hepatic glucose production and increasing insulin sensitivity, making it effective for lowering blood glucose levels. Due to its extensive clinical experience and safety profile, Metformin is often the first-line therapy prescribed to patients. Its affordability, especially as a generic medication, makes it accessible to a broad patient population. The demand for Metformin is expected to remain strong, bolstered by ongoing research into its potential benefits beyond blood glucose control, including cardiovascular protection and weight management.

Glimepiride:

Glimepiride, a sulfonylurea, is another key ingredient in the antidiabetic drug market that stimulates insulin secretion from the pancreas. It is often used in combination with Metformin to achieve optimal glycemic control in Type 2 diabetes patients. Glimepiride is recognized for its efficacy in reducing blood sugar levels; however, concerns about hypoglycemia and weight gain necessitate careful monitoring by healthcare professionals. As awareness grows regarding the importance of individualizing diabetes therapy, Glimepiride is likely to maintain a significant share of the antidiabetic drug market, particularly in patients who require additional insulin secretagogues.

Sitagliptin:

Sitagliptin, a DPP-4 inhibitor, has gained prominence in the antidiabetic drug market due to its unique mechanism of action that enhances incretin levels to improve blood glucose control. Its convenient dosing schedule and lower risk of hypoglycemia compared to other antidiabetic agents make it a popular choice among patients and healthcare providers. Sitagliptin is often utilized as an adjunct therapy with Metformin or other antidiabetic medications to achieve better glycemic control. The growing understanding of its cardiovascular benefits further enhances its attractiveness in the market, positioning Sitagliptin for ongoing growth as new treatment guidelines evolve.

Canagliflozin:

Canagliflozin, an SGLT-2 inhibitor, stands out in the antidiabetic drug market for its ability to promote renal glucose excretion while also offering cardiovascular and renal protective effects. This dual action makes Canagliflozin an appealing option for patients with Type 2 diabetes who also present with cardiovascular risks or renal impairment. The increasing body of evidence supporting its health benefits has led to expanded indications for use, and it is often combined with other antidiabetic medications to enhance treatment efficacy. As awareness of the importance of comprehensive diabetes management grows, Canagliflozin is expected to capture a larger share of the market.

Liraglutide:

Liraglutide, a GLP-1 receptor agonist, has gained traction in the antidiabetic drug market due to its multifaceted benefits, including improved glycemic control, weight loss, and cardiovascular protection. By mimicking the incretin hormones, Liraglutide enhances insulin secretion in response to meals and reduces glucagon levels, thus playing a crucial role in managing postprandial blood sugar levels. Moreover, its ability to promote weight loss makes it an attractive option for overweight or obese patients with Type 2 diabetes. As more healthcare providers emphasize holistic diabetes management, the demand for Liraglutide is expected to increase, positioning it as a key player in the antidiabetic drug landscape.

By Region

The North American market holds a significant share of the global antidiabetic drug market, primarily due to the high prevalence of diabetes, advanced healthcare infrastructure, and strong emphasis on research and development. The region accounted for approximately 40% of the market in 2023, with an estimated growth rate of around 6.5% CAGR through 2035. Government initiatives and public health campaigns aimed at diabetes awareness and management contribute to the high demand for antidiabetic medications. Furthermore, the presence of major pharmaceutical companies and a robust distribution network further strengthen the North American market.

Europe is also a critical region for the antidiabetic drug market, representing approximately 30% of the global share in 2023. The increasing prevalence of diabetes, combined with aging populations and rising obesity rates, is driving the demand for effective treatment options. The European market is expected to grow at a CAGR of 5.8% between 2025 and 2035, bolstered by favorable healthcare policies and access to innovative therapies. Additionally, collaborations between healthcare providers and pharmaceutical companies to enhance diabetes management strategies are expected to further propel market growth in this region.

Opportunities

The antidiabetic drug market is rife with opportunities for growth and innovation, particularly in the realm of personalized medicine. As the understanding of diabetes and its various phenotypes evolves, there is a growing emphasis on tailoring treatment approaches to individual patient needs. This shift toward personalized medicine presents a significant opportunity for pharmaceutical companies to develop targeted therapies that address specific metabolic pathways and patient profiles. Furthermore, the integration of digital health technologies, such as mobile applications and telemedicine, can enhance patient engagement and adherence to treatment plans. By leveraging data analytics and artificial intelligence, companies can create more effective intervention strategies and improve patient outcomes, opening new avenues for market expansion.

Another opportunity lies in the growing focus on preventive healthcare and early intervention strategies in diabetes management. With increasing awareness of the importance of lifestyle modifications in preventing Type 2 diabetes, there is a rising demand for medications that support weight management, improve metabolic health, and reduce the risk of progression from prediabetes to diabetes. Pharmaceutical companies can capitalize on this trend by developing innovative products that not only treat diabetes but also encompass preventive measures. Additionally, partnerships with healthcare systems, payers, and community organizations can facilitate access to diabetes education and screening programs, further driving the adoption of antidiabetic medications and contributing to overall market growth.

Threats

Despite the promising growth potential of the antidiabetic drug market, several threats could hinder its progress. One of the primary concerns is the increasing prevalence of generic competition as patents for leading antidiabetic medications expire. The entry of generic drugs into the market can significantly reduce the revenue for branded products, potentially limiting the resources available for research and development. Additionally, the presence of biosimilars for insulin products poses a threat to established insulin manufacturers, as they may offer lower-cost alternatives while maintaining similar efficacy and safety profiles. This competitive landscape necessitates that companies continually innovate and differentiate their products to maintain market share and profitability.

Another potential threat to the antidiabetic drug market is the growing scrutiny on pharmaceutical pricing and reimbursement policies. As healthcare costs continue to rise globally, governments and payers are increasingly focusing on value-based pricing strategies that emphasize the cost-effectiveness of medications. This scrutiny can put pressure on pharmaceutical companies to justify the pricing of their antidiabetic products, potentially leading to price reductions or restricted access for patients. Additionally, the ongoing COVID-19 pandemic has highlighted vulnerabilities in healthcare systems, which may result in shifts in priorities and funding that could impact diabetes management programs and medication access. As companies navigate these challenges, agility and adaptability will be essential to sustaining growth in the antidiabetic drug market.

Competitor Outlook

• Sanofi
• Novo Nordisk
• Merck & Co.
• AbbVie
• GlaxoSmithKline
• Pfizer
• Boehringer Ingelheim
• Johnson & Johnson
• AstraZeneca
• lilly
• Amgen
• Takeda Pharmaceutical Company
• Novartis
• Roche
• Teva Pharmaceuticals

The competitive landscape of the antidiabetic drug market is characterized by a diverse array of pharmaceutical companies, ranging from established giants to emerging players. Companies like Sanofi, Novo Nordisk, and Merck & Co. dominate the market, leveraging their extensive portfolios of antidiabetic medications and strong research and development capabilities. These organizations invest heavily in innovation, seeking to develop new formulations and delivery methods that cater to the evolving needs of diabetes patients. Furthermore, the strategic alliances and partnerships formed between these companies and healthcare systems or research institutions play a crucial role in enhancing the development of novel therapies and expanding their market presence. As competition intensifies, focusing on product differentiation and patient-centric approaches will be key for companies aiming to maintain their competitive edge in the rapidly evolving market.

Major players in the antidiabetic drug market, such as Novo Nordisk, have established themselves through a robust pipeline of insulin products and GLP-1 receptor agonists. For instance, their flagship product, insulin degludec, is known for its flexibility and extended duration of action, making it popular among patients requiring basal insulin therapy. Additionally, Novo Nordisk's strong emphasis on diabetes education and support programs enhances patient adherence and outcomes, further solidifying its market position. Similarly, Sanofi has made significant advancements in the diabetes space with its range of insulin products and the recent introduction of biosimilar insulins, reflecting the company’s commitment to addressing diverse patient needs while maintaining competitive pricing. As these companies continue to innovate, their ability to adapt to market dynamics and consumer demands will be pivotal in shaping the future of the antidiabetic drug market.

Another key player, Merck & Co., is recognized for its contributions to diabetes management through the development of DPP-4 inhibitors like sitagliptin. The company's ongoing research into the cardiovascular benefits of its diabetes medications positions it favorably in a market increasingly focused on comprehensive patient care. Moreover, Merck's commitment to global access initiatives ensures that patients worldwide can benefit from its innovative therapies, reinforcing its reputation as a market leader. In contrast, emerging players are leveraging novel technologies and unique mechanisms of action to challenge established brands, promoting innovation and potentially leading to greater patient-centric approaches in diabetes treatment. As the competitive landscape continues to evolve, collaboration, innovation, and strategic positioning will be crucial for success in the antidiabetic drug market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 lilly
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Novartis
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Novo Nordisk
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Johnson & Johnson
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceuticals
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antidiabetic Drug Market, By Application
    • 6.1.1 Type 1 Diabetes
    • 6.1.2 Type 2 Diabetes
    • 6.1.3 Gestational Diabetes
  • 6.2 Antidiabetic Drug Market, By Product Type
    • 6.2.1 Insulin
    • 6.2.2 Biguanides
    • 6.2.3 Sulfonylureas
    • 6.2.4 DPP-4 Inhibitors
    • 6.2.5 SGLT-2 Inhibitors
  • 6.3 Antidiabetic Drug Market, By Ingredient Type
    • 6.3.1 Metformin
    • 6.3.2 Glimepiride
    • 6.3.3 Sitagliptin
    • 6.3.4 Canagliflozin
    • 6.3.5 Liraglutide
  • 6.4 Antidiabetic Drug Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Antidiabetic Drug Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antidiabetic Drug market is categorized based on

By Product Type

• Insulin
• Biguanides
• Sulfonylureas
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Metformin
• Glimepiride
• Sitagliptin
• Canagliflozin
• Liraglutide

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Sanofi
• Novo Nordisk
• Merck & Co.
• AbbVie
• GlaxoSmithKline
• Pfizer
• Boehringer Ingelheim
• Johnson & Johnson
• AstraZeneca
• lilly
• Amgen
• Takeda Pharmaceutical Company
• Novartis
• Roche
• Teva Pharmaceuticals